AU2021339978A1 - Single domain antibodies that target sars-cov-2 - Google Patents

Single domain antibodies that target sars-cov-2 Download PDF

Info

Publication number
AU2021339978A1
AU2021339978A1 AU2021339978A AU2021339978A AU2021339978A1 AU 2021339978 A1 AU2021339978 A1 AU 2021339978A1 AU 2021339978 A AU2021339978 A AU 2021339978A AU 2021339978 A AU2021339978 A AU 2021339978A AU 2021339978 A1 AU2021339978 A1 AU 2021339978A1
Authority
AU
Australia
Prior art keywords
seq
cdr3
single domain
cdr2
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021339978A
Other languages
English (en)
Other versions
AU2021339978A9 (en
Inventor
Jiandong HUO
James Naismith
Raymond Owens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosalind Franklin Institute
Original Assignee
Rosalind Franklin Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2014451.5A external-priority patent/GB202014451D0/en
Priority claimed from GBGB2014453.1A external-priority patent/GB202014453D0/en
Priority claimed from GBGB2108319.1A external-priority patent/GB202108319D0/en
Application filed by Rosalind Franklin Institute filed Critical Rosalind Franklin Institute
Publication of AU2021339978A1 publication Critical patent/AU2021339978A1/en
Publication of AU2021339978A9 publication Critical patent/AU2021339978A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2021339978A 2020-09-14 2021-09-14 Single domain antibodies that target sars-cov-2 Abandoned AU2021339978A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2014453.1 2020-09-14
GBGB2014451.5A GB202014451D0 (en) 2020-09-14 2020-09-14 Single domain antibodies
GB2014451.5 2020-09-14
GBGB2014453.1A GB202014453D0 (en) 2020-09-14 2020-09-14 Linker
GBGB2108319.1A GB202108319D0 (en) 2021-06-10 2021-06-10 Single domain antibodies
GB2108319.1 2021-06-10
PCT/GB2021/052383 WO2022053839A1 (en) 2020-09-14 2021-09-14 Single domain antibodies that target sars-cov-2

Publications (2)

Publication Number Publication Date
AU2021339978A1 true AU2021339978A1 (en) 2023-05-04
AU2021339978A9 AU2021339978A9 (en) 2024-10-10

Family

ID=77951755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021339978A Abandoned AU2021339978A1 (en) 2020-09-14 2021-09-14 Single domain antibodies that target sars-cov-2

Country Status (7)

Country Link
US (1) US20230374116A1 (https=)
EP (1) EP4211157A1 (https=)
JP (1) JP2023542107A (https=)
KR (1) KR20240102916A (https=)
AU (1) AU2021339978A1 (https=)
CA (1) CA3192456A1 (https=)
WO (1) WO2022053839A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813759B (zh) * 2022-03-21 2025-11-28 中国科学院微生物研究所 纳米抗体r14的构建体及其应用
CN114736293B (zh) * 2022-06-14 2022-09-02 中国农业科学院生物技术研究所 SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用
CN117603358B (zh) * 2023-02-24 2024-11-01 中国科学院微生物研究所 一种广谱新型冠状病毒的双特异性抗体
CN118255878A (zh) * 2024-04-15 2024-06-28 深圳细胞谷生物医药有限公司 SARS-CoV-2驼源纳米抗体或其抗原结合片段、及其组合物和应用
GB202413879D0 (en) 2024-09-20 2024-11-06 Rosalind Franklin Inst Single domain antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법

Also Published As

Publication number Publication date
WO2022053839A1 (en) 2022-03-17
EP4211157A1 (en) 2023-07-19
US20230374116A1 (en) 2023-11-23
KR20240102916A (ko) 2024-07-03
JP2023542107A (ja) 2023-10-05
AU2021339978A9 (en) 2024-10-10
CA3192456A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
US20230374116A1 (en) Single domain antibodies that target sars-cov-2
AU2020286284B2 (en) Novel anti-CD39 antibodies
WO2021244089A1 (zh) 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用
JP2020171288A (ja) インフルエンザヘマグルチニンに対する結合分子及びその使用
US20240207401A1 (en) Coronavirus antibody
US20240270826A1 (en) Antibodies that bind sars-cov-2 spike protein
US20230357364A1 (en) Covid-19 antibodies and uses thereof
JP2023534922A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
KR20240142594A (ko) 코로나바이러스 sars-cov-2의 스파이크 단백질에 결합할 수 있는 항체
Song et al. Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2
Fu et al. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike
US20240228595A1 (en) Methods for Monoclonal Antibody Generation
US20230382979A1 (en) Anti-sars-cov-2 antigen antibodies and related compositions and methods
US20230399385A1 (en) Neutralizing antibodies against sars-cov-2
WO2022068844A1 (en) Neutralizing antibody against sars-cov-2
WO2021203397A1 (en) Anti-sars-cov-2 antibodies and uses thereof
CN117042799A (zh) 靶向sars-cov-2的单结构域抗体
US20240401239A1 (en) Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2024068744A1 (en) Antivirals against human parainfluenza virus
CA3267635A1 (en) Antivirals against human parainfluenza virus
Fu et al. The humanized nanobody RBD-1-2G tolerates the spike N501Y mutation to neutralize SARS-CoV-2
US20240262892A1 (en) Neutralizing antibodies against sars-cov-2
WO2022006562A1 (en) Multispecific coronavirus antibodies

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period